Skip to content
All articles

Multicenter phase 2 trial of neoadjuvant serplulimab plus nab-paclitaxel and epirubicin for high-risk, early HR+/HER2- breast cancer

Prof. Zhenzhen Liu
Prof. Zhenzhen Liu

The phase 2 HELEN-B 018 trial, at six centers in China, evaluated serplulimab plus nab-paclitaxel and epirubicin in high-risk, early HR+/HER2- breast cancer. Eligible patients were adults with T1cN1-3 or T2-4 any N and Ki-67 ≥20%. Participants received 6 cycles of nab-paclitaxel (260 mg/m2) plus epirubicin (75 mg/m2) on day 1 and serplulimab 4.5 mg/kg on day 3 every 3 weeks.The primary endpoint was pathologic complete response (pCR) rate. A total of 101 participants started treatment and were included in the full analysis set. pCR was achieved in 23 patients (22.8%: 95% CI 15.3-32.4); RCB 0 or 1 was achieved in 34 patients (33.7%; 24.8-43.8). The pCR rate was higher in PD-L1-positive tumors (combined positive score ≥ 1; pCR 44.4%; 95% CI 30.0-59.9) than in PD-L1-negative tumors (5.4%; 1,4-15.8). During the neoadjuvant phase, 30 patients (29.7%) experienced grade 3 or 4 treatment-related adverse events.; there were no treatment-related deaths. The authors conclude that serplulimab combined with nab-paclitaxel showed antitumor activity and manageable safety in patients with HR+/HER2- breast cancer, and the pCR rate was higher in PD-L1-positive tumors. These findings support further evaluation of this regimen in randomized controlled trials.

Original publicationaacrjournals.org
Read the publication